fda semaglutide weight loss Novo Nordisk's weight-loss pill wins approval FDA has approved a new,

However, Wegovy (semaglutide) works only through the GLP-1 receptor, while Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors

A conceptual model of food cue reactivity, Nutrients (2023) Human drug compounding, Food and Drug Administration (2024) Compounding when drugs are on FDAs drug shortages list, Food and Drug Administration (2024) Your guide to FDA-approved medicines that contain semaglutide, Novo Nordisk FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food & Drug Administration (2024) Wegovy, DailyMed (2024) FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness, Food and Drug Administration (2024) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) OFA v

10.1016/j.soard.2014.01.010 [DOI] [PubMed] [Google Scholar] 120.Hesse UJ, Lenz J, Giulini L, Vladimirov M, Dubecz A, Stein HJ

The European Medicines Agency (EMA) has confirmed that Novo Nordisks Ozempic and Wegovy may cause non-arteritic anterior ischemic optic neuropathy (NAION) , a serious eye condition that can lead to permanent vision loss

Vissers, D